RIPK1-IN-4

• UNSPSC Description:

  RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase[1].

• Target Antigen:

  RIP kinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ripk1-in-4.html

• Purity:

  98.89

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  CC(C)(C1=CC(NC(NC2=CC=C(C3=CC=CC4=C3C=CN=C4N)C=C2)=O)=NO1)C

• Molecular Weight:

  401.46

• References & Citations:

  [1]Harris PA, et al. Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Med Chem Lett. 2013 Nov 4;4(12):1238-43.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1481641-08-0